

1 **T cell response to intact SARS-CoV-2 includes coronavirus cross-reactive and variant-specific**
2 **components**

3

4 Lichen Jing ^{1,*}

5 Xia Wu ^{1,*}

6 Maxwell P. Krist ^{1,*}

7 Tien-Ying Hsiang ²

8 Victoria L. Campbell ¹

9 Christopher L. McClurkan ¹

10 Sydney M. Favors ¹

11 Lawrence A. Hemingway ¹

12 Charmie Godornes ¹

13 Denise Q. Tong ¹

14 Stacy Selke ³

15 Angela C. LeClair ¹

16 Chu-Woo Pyo ⁷

17 Daniel E. Geraghty ⁷

18 Kerry J. Laing ¹

19 Anna Wald ^{1,3,6,8}

20 Michael Gale Jr. ^{2,4,5}

21 David M. Koelle ^{1,3,5,8,9,10}

22

23 * Contributed equally

24 ¹ Department of Medicine, University of Washington

25 ² Department of Immunology, University of Washington

26 ³ Department of Laboratory Medicine and Pathology, University of Washington

27 ⁴ Center for Innate Immunity of Immune Disease, Department of Immunology, University of
28 Washington

29 ⁵ Department of Global Health, University of Washington

30 ⁶ Department of Epidemiology, University of Washington

31 ⁷ Clinical Research Division, Fred Hutchinson Cancer Research Center

32 ⁸ Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center

33 ⁹ Benaroya Research Institute, Seattle

34

35 ¹⁰ Correspondence: David Koelle, 750 Republican Street, Room E651, Seattle, WA, 98109, 206

36 616 1940, dkoelle@medicine.washington.edu

37

38

39 **Funding**

40 NIH contract HHSN75N93019C00063 (DMK) and HHSN272201600027C (DEG), and NIH
41 grants AI163999 (DMK, XW), and AI118916, AI104002, and AI115296 (MG).

42

43 **Acknowledgements**

44

45 We thank the participants, the University of Washington Virology Research Clinic and
46 Immunology Cell Analysis Facility, the Flow Core at Seattle Children's Research Institute, Jesse
47 Bloom, Katharine Crawford, Keara Malone, Andrea Loes, and Allison Greaney for SARS-CoV-2
48 plasmids, Ralph Baric for Vero-E6-USAMRIID cells and SARS-CoV-2-strain WA1-GFP, and
49 Thomas Snyder and Adaptive Biotechnologies for Immunoseq™ sequencing.

50

51 **Author Contributions**

52

53 Conceptualization: DMK, LJ, XW; Data curation and bioinformatic analysis: XW, LJ, MPK, DMK;
54 Funding acquisition: MG, DEG, DMK; Investigation: LJ, XW, MPK, VLC, T-YH, CLM, C-WP,
55 SMF, LH, CG, DT, KJL, DG; Data management: SS; Clinical protocol: AW, ACL; Supervision:
56 DMK, MG; Writing: DMK, XW, MPK, LJ, KL.

57

58 **Abstract**

59

60 SARS-CoV-2 provokes a brisk T cell response. Peptide-based studies exclude antigen
61 processing and presentation biology and may influence T cell detection studies. To focus on
62 responses to whole virus and complex antigens, we used intact SARS-CoV-2 and full-length
63 proteins with DC to activate CD8 and CD4 T cells from convalescent persons. T cell receptor
64 (TCR) sequencing showed partial repertoire preservation after expansion. Resultant CD8 T cells
65 recognize SARS-CoV-2-infected respiratory cells, and CD4 T cells detect inactivated whole viral
66 antigen. Specificity scans with proteome-covering protein/peptide arrays show that CD8 T cells
67 are oligospecific per subject and that CD4 T cell breadth is higher. Some CD4 T cell lines
68 enriched using SARS-CoV-2 cross-recognize whole seasonal coronavirus (sCoV) antigens, with
69 protein, peptide, and HLA restriction validation. Conversely, recognition of some epitopes is
70 eliminated for SARS-CoV-2 variants, including spike (S) epitopes in the alpha, beta, gamma,
71 and delta variant lineages.

72

73 **Introduction**

74

75 The acquired immune response to SARS-CoV-2 can limit infection, as shown by protection from
76 re-infection (1) and the efficacy of vaccines (2). While antibodies can prevent infection and
77 disease, T cell depletion studies of convalescent or vaccinated animals strongly suggest active
78 roles for T cells (3). Many studies have defined regions of the predicted SARS-CoV-2 proteome
79 that can activate T cells in blood (4, 5). This work typically uses single or pooled peptides, or
80 peptide-based reagents such as HLA multimers. Some workflows result in cell death that limit
81 follow-up, while others, such as activation-induced marker (AIM)-based cell sorting (6) allow
82 recovery of live cells for downstream work. Taken together, peptide-based studies provide a
83 large thesaurus of reactive peptides, and in some cases, relevant HLA restricting alleles and
84 TCR sequences. However, validation of reactivity with whole virus or complex antigens is less
85 frequently reported.

86

87 The present report used PBMC from a cohort of coronavirus-19 (COVID-19) convalescent
88 persons (7-10) to begin to study T-cell responses to SARS-CoV-2 in the contexts of direct- and
89 cross-presentation of complex viral antigens. Validation with proteome-covering full-length
90 protein and peptide sets allowed definition and confirmation of many individual epitopes.

91 Expanded responder cell populations also permit detailed study of HLA restriction, functional
92 avidity, cross-recognition of sCoV, and recognition of circulating SARS-CoV-2 variants including
93 variants being monitored (VBM) and variants of concern (VOC).

94

95 Estimates of the overall magnitude of the CD4 and CD8 T cell response to SARS-CoV-2, as a
96 percent of circulating PBMC at times soon after clinical recovery are around the 0.5-1% level
97 based on the summation of peptide reactivities (4, 11, 12). We were interested in benchmarking
98 peptide-based estimates for SARS-CoV-2 to the levels of reactivity to whole viral antigen, and in

99 comparing epitope specificities determined using peptide sets and more complex antigens. It is
100 well established that T cell clonotypes show cross-reactivity to unrelated peptide epitopes
101 presented by a single HLA allele, for example cross-recognition of disparate influenza and EBV
102 peptides with HLA A*02:01 (13), pathogenic cross-recognition of influenza and self-epitopes
103 (14), and potentially beneficial cross-reactivity between viruses and tumor antigens (15). The
104 same TCR can also recognize peptides presented by divergent HLA alleles, for example the
105 alloreactivity of herpes simplex virus (HSV)- or EBV-specific T cells against HLA-mismatched
106 antigen presenting cells (APC) bearing endogenous peptides (16, 17). Reactivities detected
107 solely using SARS-CoV-2 peptide sets could include such cross-reactivity. The use of complex
108 SARS-CoV-2 antigens to enrich responses also incorporates antigen processing and
109 presentation steps, such as proteosomal cleavage, peptide transport into the endoplasmic
110 reticulum and trimming during HLA loading, that can be influenced by flanking sequences within
111 proteins, as well as potentially incorporating post-translational modifications and cryptic ORFs
112 absent from peptide sets (18, 19). We also studied recognition of whole SARS-CoV-2 at the
113 effector stage: CD8 T cell assays used infected bronchial epithelial cells HLA-matched to CD8
114 effector T cells, while CD4 T cell readouts used SARS-CoV-2 antigen and appropriate APC.
115 Importantly, we also checked if T cells enriched using simpler peptide or protein antigens could
116 recognize whole virus.

117
118 SARS-CoV-2 shares genomic structure and sequence motifs with sCoV. Cross-reactivity with
119 sCoV has been described (20) but is less studied in the whole virus context. SARS-CoV-2 also
120 shows modest sequence variation, and variants and deletions emerge within-subject in immune
121 suppressed persons (21), and within populations (22). In the present report, we use culture-
122 amplified T cell responders to probe recognition of sCoV and variant SARS-CoV-2 T cell
123 epitopes.

124

125 **Results**

126

127 **Subjects and specimens.** We studied 26 specimens from 12 subjects (Supplementary Table
128 1) with COVID-19 in March or April 2020, prior to detection of VOCs in the study region (23).
129 Each subject reported SARS-CoV-2 RNA detection, positive serum or plasma anti-S domain 1
130 and anti-N IgG, and SARS-CoV-2 neutralizing antibody (nAb) titer $\geq 1:40$ (7). Median age was
131 56 (range 32 to 72) and sex was balanced. Amongst 4 hospitalized subjects, 3 required
132 intensive care. Median illness duration was 16 days (range 4 to 32). PBMC were obtained a
133 median of 138 days after recovery (range 31 to 256). We used several methods to enrich
134 SARS-CoV-2-specific T cells for detailed studies (outlined in Supplementary Fig. 1).

135

136 **PBMC T cell responses to whole SARS-CoV-2 antigen.** SARS-CoV-2 WA1 antigen was
137 prepared from infected cells, rather than from purified virions, to include non-structural proteins
138 (NSPs) (24). We used dual expression of CD137 and CD69 for analytic AIM and to sort cells for
139 expansion (Fig. 1) (25). We observed a median of 0.16% (range 0.089% to 0.33%) of CD4 T
140 cells were AIM (+) (n=5, Supplementary Table 2). Responses to mock antigen were low
141 (median 0.026%, range 0.009%-0.061%). Responses to viral antigen were higher than to mock
142 antigen ($p = 0.0078$ by pair-wise analysis); the median net response was 0.13%. Absolute and
143 net responses to whole SARS-CoV-2 antigen in HD PBMC were low, with no significant net
144 virus-specific signal (Supplementary Fig. 2B). We sorted a median of 389 AIM (+) CD4 T cells
145 (machine counts, range 375 - 2,138) per specimen from the 5 COVID-19 convalescent subjects
146 (Supplementary Table 2).

147

148 After expansion with a generalized mitogenesis protocol, T cell line (TCL) functional enrichment
149 was measured as reactivity to whole killed SARS-CoV-2. Autologous PBMC used as APC were
150 dump-gated and IFN- γ and IL-2 expression used to enumerate SARS-CoV-2-specific CD4 T

151 cells (8, 11). We observed robust TCL enrichment of virus-reactive CD4 T cells. For example,
152 participant W003 TCL had net 8.14% of cells responding to whole SARS-CoV-2 (Fig. 1C), a 61-
153 fold enrichment over the PBMC CD4 T cell AIM signal. Enrichment ranged from 41- to 201-fold
154 for the 5 subjects (Supplementary Table 2).

155
156 Both monocytes in fresh PBMC and moDC can process and present antigens to CD4 T cells.
157 Higher levels of PBMC CD4 T cell activation were noted when autologous DC were used as
158 initial APC (Fig. 1B) compared to direct addition of killed virus to PBMC. Background signal for
159 mock antigen also slightly increased (median 0.16%, range 0.11%-0.47%). The median net
160 proportion of AIM (+) CD4 T cells was 0.66% (range 0.35% to 2.43%) across 12 samples. Use
161 of moDC allowed the sorting of a median of 11,320 activated CD4 T cells per specimen (range
162 8,190 to 19,860), from which 20% were culture-expanded (Supplementary Table 2) and 80%
163 used for *ex vivo* TCR sequencing.

164
165 In addition to presentation to CD4 T cells, moDC can cross-present inactivated antigen to CD8
166 T cells. Using moDC, we observed specific CD8 T cell activation as measured by CD69 and
167 CD137 co-expression (Fig. 1B). Negative control antigen was immunologically silent. We did not
168 detect PBMC CD8 T cell responses in HD (Supplementary Fig. 2). As with CD4 T cells, higher
169 net proportions of AIM (+) CD8 T cells were noted with moDC (n = 12, median 0.95%, range
170 0.27 to 1.62%) than without (n = 5, median 0.033%, range 0.013%-0.29%) (Supplementary Fig.
171 2B, Supplementary Table 2). A median of 842 CD8 T cells (range, 411 - 2,611) were expanded
172 per specimen, while 80% of the AIM-sorted cell populations were TCR-sequenced.

173
174 Two subjects were studied using moDC at five time points each between 32 to 256 days after
175 recovery from COVID-19. Decreasing CD4 and CD8 AIM (+) abundance was noted over time
176 (Supplementary Table 2). Subject W005 had consistently higher CD4 than CD8 T cell

177 responses, with the ratio of activated cells ranging from 1.54 to 3.15. A reciprocal pattern was
178 seen in subject W012, with consistent CD4/CD8 ratios of AIM (+) cells < 1.

179

180 **TCR repertoire tracking during T cell expansion.** We used the moDC workflow to present
181 whole SARS-CoV-2 antigen (above), and analyzed AIM (+) CD4 and CD8 T cells from three
182 subjects at two time points each. A portion of AIM (+) cells were directly sequenced, and a
183 portion sequenced after expansion, with a genomic DNA-based method (26). A median of
184 6.75% of CDR3 aa sequences detected *ex vivo* were found in expanded cultures. Reciprocally,
185 a median of 16.75% of productive CDR3 aa sequences in the expanded cultures were detected
186 in the corresponding *ex vivo* samples (representative data, Supplementary Fig. 3A). CDR3
187 abundances showed excellent agreement for AIM (+) cells after one vs two expansions
188 (representative data, Supplementary Fig. 3B). A possible factor contributing to repertoire
189 differences *ex vivo* vs. post-expansion is poor recovery of DNA from small *ex vivo* specimens.
190 Amongst the 12 *ex vivo* samples, the median number of productive CDR3 gene rearrangements
191 reported was 11.6% (range, 4.9-21.7%) of the sorting cell counts.

192

193 **Alternative generation of polyclonal SARS-CoV-2-reactive T cells.** As an alternative
194 approach to retains an antigen processing requirement, SARS-CoV-2 proteins were expressed
195 in COS-7 or HeLa cells. These were harvested, inactivated, and added to PBMC without (COS-
196 7) or with (HeLa) autologous moDC. Small increments in AIM-positive CD4 or CD8 T cells were
197 detectable compared to mock antigen (representative data, Supplementary Fig. 4A). Finally,
198 CD8 or CD4 T cells proliferating (representative data, Supplementary Fig. 5A) to SARS-CoV-2
199 peptide pools were sorted and expanded.

200

201 **CD8 T cell recognition of infected cells.** CD8 T cell recognition typically requires HLA
202 matching. HBEC3-KT-A are permissive for SARS-CoV-2 replication and are HLA A*03:01 (+)

203 (Supplementary Table 3). For effector CD8 T cells we stimulated PBMC from HLA A*03:01 (+)
204 participant W003 with autologous DC loaded with S protein-expressing HeLa cells, sorted AIM
205 (+) CD8 T cells, expanded them, and showed they recognized S protein in the HLA A*03:01
206 context (Supplementary Fig. 6A). A reactive peptide, S 377-389, was found using peptide
207 matrices (Supplementary Fig. 6B) containing the HLA A*03:01-restricted epitope S 378-386
208 (27). A fluorescent A*03:01-S 378-386 tetramer allowed further enrichment of CD8 T cells
209 (Supplementary Fig. 6C). We then examined if S protein could be processed and presented by
210 virus-infected cells. CD8 T cells specifically recognized SARS-CoV-2-infected HBEC3-KT-A
211 cells (Fig. 2A). Specificity control HLA A*03:01-restricted, tetramer-enriched CD8 T cells,
212 specific for an unrelated polyomavirus epitope in MCPyV (28), were active when tested with
213 polyomavirus peptide-pulsed HBEC3-KT-A positive controls (Fig. 2B) but did not recognize
214 SARS-CoV-2-infected target cells (Fig. 2A).

215
216 **CD8 T cell responses to full-length SARS-CoV-2 proteins.** CD8 T cell target diversity was
217 studied using whole virus stimulation followed by SARS-CoV-2 proteome-wide scans using
218 subject-specific HLA A and B aAPC panels. A complex response was observed for subject
219 W005, hospitalized in the ICU and studied 32 days after recovery, by incorporating DC boosting.
220 This subject had an HLA B*15:02-restricted response to NSP2, HLA A*11:01- and B*15:02-
221 restricted responses to nucleoprotein, and an HLA B*51:01-restricted response to ORF3A (Fig.
222 3A). Multiple proteins were positive for subject W012, while subject W001, studied using moDC,
223 only showed responses to ORF9B (summarized in Fig. 4A). Even when moDC were not used,
224 the aAPC-proteome panels were successful for bulk AIM-enriched CD8 TCL enriched with
225 whole virus. For example, subject W010 had a single HLA A*01:01-restricted response detected
226 for NSP3 (Fig. 3B). This was confirmed at the peptide level (Fig. 3C), allowing tetramer
227 enrichment (Fig. 3D) and use of tetramer-enriched cells confirmed as ORF- and peptide-
228 reactive (Fig. 3E) to determine functional avidity (Fig. 3F).

229

230 **CD4 T cell responses to full-length SARS-CoV-2 proteins.** AIM-sorted, expanded CD4 TCL,
231 enriched with or without DC boosting, were similarly tested proteome-wide. Each SARS-CoV-2
232 ORF or cleaved polypeptide product of ORFs polypeptide (PP)1a and PP1ab(29) was
233 expressed (30). Readout assays included Th1 cytokine ICS (supplementary Fig. 7A),
234 proliferation (supplementary Fig. 7B), and IFN- γ secretion (supplementary Fig. 7C). Across 17
235 specimens from 8 persons, a median of 7 proteins were recognized per specimen (range, 3 to
236 15) (summarized in Fig. 4B). The SARS-CoV-2 proteins recognized in the highest percentage of
237 participants were S, membrane (M), nucleoprotein (N), and ORF9B (Fig. 4B). Reactivity to
238 ORF3A, ORF7A, NSP2, and NSP3 were also noted in 50% or more of participants. Because
239 DC were not used for all specimens and few participants were studied, conclusions about
240 antigen breadth and dominance remain preliminary. We noted that over time, most within-
241 participant protein-level responses were consistent. For example, participant W005 recognized
242 NSP2, NSP13, and NSP16 at almost all time points (Fig. 4B).

243

244 **CD8 T cell epitopes.** TCL initiated with diverse workflows (Supplementary Fig. 1) were used.
245 moDC-whole virus stimulation of PBMC yielded peptide epitopes (examples, Supplementary
246 Fig. 8) to confirm ORF-level hits (Fig. 3A, Fig. 4A). PBMC stimulation with SARS-CoV-2 proteins
247 with DC, followed by AIM sorting also yielded cultures that reacted with the relevant ORF and
248 discrete peptides (example, Supplementary Fig. 4A, 4B), as did PBMC stimulation with pooled
249 peptides followed by sorting of proliferated cells (Supplementary Fig. 5A, Supplementary Fig.
250 4C). Overall, integrated across CD8 TCL and eliminating redundancies, CD8 T cells reactive
251 with 25 SARS-CoV-2 epitopes in the context of 8 HLA class I alleles were obtained
252 (Supplementary Table 4).

253

254 **CD4 T cell epitopes.** TCL initiated with several workflows were tested to define peptide
255 epitopes. Importantly, when TCL were started with peptide pools (as in Supplementary Fig. 5A),
256 the resultant TCL recognized whole virus lysate and full-length protein (Supplementary Fig. 5B)
257 as well as peptides (Supplementary Fig. 5C), suggesting epitopes discovered with peptides are
258 relevant to viral infection. IFN- γ and proliferation readouts corresponded (representative data,
259 Supplementary Fig. 9) and we summarize epitopes defined with either or both readouts.
260 Cultures initiated with complex antigen, such as from participant W001 using moDC-assisted
261 stimulation with whole virus, yielded multiple reactive peptides (representative data,
262 Supplementary Fig. 10). Overall, CD4 T cell epitopes were detected in 13 SARS-CoV-2
263 proteins. Responses were diverse within-person. For specimen 1 from participant W001
264 (Supplementary Table 1), 55 epitopes were confirmed in 7 proteins, including 27 epitopes in S,
265 7 each in N and NSP3, 6 in ORF3A, 5 in M, 2 in ORF9B, and 1 in ORF7A (Supplementary
266 Table 5). Similarly, in participant W005 studied one month after recovery, 65 CD4 T cell
267 epitopes were identified in 10 proteins. Altogether, we observed 240 CD4 T cell peptide
268 reactivities from 8 persons (Supplementary Table 5). These correspond to 172 unique SARS-
269 CoV-2 peptides (Supplementary Table 5). Amongst these, we found 70 epitopes in S protein, 26
270 in N protein, and 23 in M protein, with fewer in ORFs 3A, 7A, 8, and 9, and NSPs 1, 2, 3, 4, 6,
271 and 7. Peptides with CD4 T cell recognition by at least half the population studied included M
272 69-81, M 177-189, S aa 133-145, S 165-177, N 289-301, and N 349-361.

273

274 **CD4 T cell HLA restriction and functional avidity.** Studies of CD4 T cell HLA restriction and
275 estimated functional avidity (representative data, Supplementary Fig. 11) yielded HLA locus-
276 level data on 118 of 123 (96%) peptides tested. Amongst these, 84 (72%) were HLA DR-
277 restricted, 23 (20%) were HLA DQ-restricted, and 11 (8%) were HLA DP-restricted
278 (Supplementary Table 5). HLA restriction at the locus level was generally identical if two
279 participants recognized the same peptide, but there were exceptions. S protein aa 165-177 was

280 HLA DP-restricted in 4 participants and HLA DR-restricted in 2. Allele-level restriction was
281 determined using aAPC (representative data, Supplementary Fig. 11A, 11B). We observed
282 presentation by 10 distinct HLA DRB1, DRB3, and DRB4 alleles (Supplementary Table 5).
283 Some peptides in SARS-CoV-2 S, M, and N proteins were presented by both DRB1 and either
284 DRB3 or DRB4 (representative data, Supplementary Fig. 11C) or dual DRB3 alleles (not
285 shown). Functional avidity data were available for 124 CD4 T cell epitopes (representative data,
286 Supplementary Fig. 11, summarized in Supplemental Table 5). Responses at 1 and 10 ng/ml
287 peptide were noted for 4 and 10 epitopes, respectively. S 165-177 was particularly potent, with
288 responses at 1 or 10 ng/ml for 5 of 6 subjects.

289

290 **Recognition of seasonal coronaviruses.** Cross-recognition of SARS-CoV-2 and sCoV
291 peptide has been documented (6, 20), but less is known about recognition of complex viral
292 antigens. We found that polyclonal CD4 TCL each of three subjects studied, enriched from
293 PBMC using whole SARS-CoV-2 antigen and moDC, cross-recognized either whole OC43 or
294 whole 229E cell-associated virus (Fig. 5A). Control mock-infected virus preparations were
295 negative. An additional CD4 TCL enriched using whole SARS-CoV-2 antigen without moDC
296 also cross-recognized OC43. For subject W001, S proteins from both viruses were both
297 antigenic (Fig. 5B), as were both homologs of a peptide in S. The HLA restricting allele was
298 established as HLA DRB1*15:01 (Fig. 5C). Cross-recognition of an HLA DP-restricted peptide
299 that is nearly identical in SARS-CoV-2, OC43, and HKU1 N proteins was also observed
300 (Supplementary Fig. 12).

301

302 **Recognition of SARS-CoV-2 variants.** To choose variants for study we correlated SARS-
303 CoV-2 T cell epitopes detected using Wu-1/WA1 reagents with variants both in early 2020 data
304 and in early 2021 VBM, concentrating on the B.1.1.7, B.1.351, and P1 lineages. Polyclonal CD8
305 TCL were recovered from subject W004 using an S peptide pool (Supplementary Fig. 5A).

306 Potent recognition of strain Wu-1 peptides 269-277 YLQ and 417-425 KIA, HLA A*02:01-
307 restricted epitopes (27), was observed (Fig. 6). There was no recognition of variants with
308 substitutions K417N and K417T which are present in the B.1.351 and P.1 lineages, respectively.
309 Epitope-specific T cells enriched with tetramers (Supplementary Fig. 13A) detected full-length S
310 processed by HLA A*02:01-transfected aAPC (Supplementary Fig. 13B), but failed to recognize
311 S K417T or the full-length SARS-CoV-2 S variant from lineage B.1.351 bearing K417T.
312 Responses to S from B.1.1.7, which does not have an aa417 substitution, were intact. Control
313 CD8 T cells specific for S aa 269-277 YLQ, unchanged in these variants, were not affected
314 (Supplementary Fig. 13B). We also observed loss of CD8 TCL reactivity to SARS-CoV-2 S
315 F490S in the HLA A*29:02-restricted aa 489-497 epitope, to S K378N in the HLA A*03:01-
316 restricted aa 378-386 epitope, and to M (membrane) T175M in the HLA A*11:01 aa 169-181
317 epitope (Supplementary Fig. 13, summarized in Table 1).
318
319 Variant changes could also influence CD4 T cell recognition (primary data, Supplementary Figs.
320 14-17). In addition to loss of recognition of variant aa in B.1.1.7 (effects summarized in Table 1
321 and Fig. 7) and/or P.1 lineages, we also noted strain-specific recognition of B.1.1.7-associated
322 sequences that were already prevalent in early 2020 and not unique to VBM (example,
323 Supplementary Fig. 10, indicated in blue). A graphical summary of variants evaluated in S (Fig.
324 7) shows a mixture of responses that are either preserved, partially reduced in dose-response
325 assays, or abrogated when tested with variant peptides.

326 **Discussion**

327

328 The T cell response to SARS-CoV-2 is functionally important (31). Studies have correlated T
329 cell kinetics, magnitude or phenotypes with disease in apparently immune competent persons
330 with delayed or dis-coordinated immunity and poor clinical outcome (8, 32). T cell responses
331 have been linked to protection from re-infection (33). Disease states and iatrogenic treatments
332 that decrease T cell responses can prolong live virus shedding (34, 35). Cooperation between T
333 and B cells, such as antigen-specific CD4 T_{FH} (36), also suggest that T cells are involved in
334 pathogen control. Supporting this, S-specific CD4 T cell TCR breadth and depth correlate with
335 nAb titers in COVID-19 convalescent persons (9). CD8 T cell depletion data in non-human
336 primates indicate that these effectors contribute to vaccine-induced protection (3).

337

338 Many groups have detected responses to SARS-CoV-2 epitopes using peptide-based
339 technologies (31), but less work has focused on T cell reactivity to complex antigens such as
340 whole virus or full-length proteins. Both T cell priming, and effector responses of memory T
341 cells, occur *in vivo* in the context of viral infection and/or loading of antigen into various APC,
342 with important differences for HLA class I and II (37). In the present report, we leveraged the
343 ability of moDC to cross-present whole viral antigen to CD8 T cells, and to present viral antigen
344 to CD4 T cells, to enrich polyclonal SARS-CoV-2-specific T cells. Similar studies are rare; in one
345 report, live virus induced subtle IFN- γ expression in convalescent T cells, but confirmation of
346 virus specificity was not documented (38). Using established (25, 30, 39-42) readout methods,
347 TCL created after whole virus or simpler antigen stimulation were used to study the breadth and
348 specificity of the T cell response, reactivity to virus-infected cells, and recognition of sCoV and
349 SARS-CoV-2 variants.

350

351 Acute COVID-19 most severely effects the respiratory tract, and while autopsy surveys can
352 detect virus body-wide (43), it is likely that T cell contributions to host defense and possibly to
353 inflammatory damage occur mostly in the respiratory tract and draining lymph nodes. Cytotoxic
354 T cells have the potential to kill SARS-CoV-2 infected cells and thus reduce viral progeny and
355 further cell infection. To date, reports of the ability of T cells to recognize SARS-CoV-2 infected
356 cells are limited. We have begun such studies using the HBEC3-KT-A. We previously showed
357 that HBEC3-KT-A cells are permissive for expression of SARS-CoV-2 ORF6 protein after
358 infection, (44) and that infected cells stain positively for S protein and viral RNA (45). We find
359 that HLA-matched S-specific CD8 T cells recognize virally infected cells. HBEC3-KT cells can
360 differentiate into ciliated and mucus-producing goblet cells *in vitro* (46), and *in vivo*, ciliated
361 respiratory epithelial cells have the highest levels of SARS-CoV-2 RNA (47). Zhang *et al.* have
362 reported that the SARS-CoV-2 ORF8 protein can down-regulate HLA class I and limit CD8 T
363 cell killing of peptide-sensitized target cells (48). Wagner *et al.* have shown recognition of
364 SARS-CoV-2-infected cancer-origin lung alveolar cells by overexpressing ACE2 and exogenous
365 HLA class I alleles. Effector cells were allogeneic T cells engineered to express TCRs specific
366 for SARs-CoV-2 (49). Many viruses encode CD8 T cell evasion functions, effects that can be
367 selective for non-transformed, physiologically relevant APC (50). We are currently optimizing
368 SARS-CoV-2 infection of primary human nasal epithelial cells, differentiated to ciliated and
369 goblet phenotypes, and pursuing CD8 recognition studies of other SARS-CoV-2 proteins, target
370 cell killing, and reduction of viral yield in CD8 T cell studies.

371

372 A cytotoxic CD4 T cell phenotype has been detected during acute SARS-CoV-2 infection (51,
373 52). Upper and lower respiratory tract epithelial cells can display HLA class II required for CD4 T
374 cell recognition, and pulmonary alveolar macrophages are excellent APC for CD4 T cells and
375 are abundant in COVID-19 pneumonia, containing SARS-CoV-2 antigen (53). Thus, CD4 T cell

376 recognition of whole viral antigen could be relevant to lung infection, again with either salutary or
377 damaging effects.

378

379 We studied T cell responses from relatively few persons and have not attempted to evaluate
380 novelty per-epitope given the plethora of work in this area. Coverage of the entire viral
381 proteome may, however, enable some novel insights. Mass spectroscopy suggests a large
382 spectrum in SARS-CoV-2 NSP abundance in infected cell cultures (54, 55) and *in vivo* (56, 57).
383 Previous studies suggesting that viral protein abundance is associated with CD4 T cell
384 immunodominance (39, 58) are supported by our finding of prevalent and poly-specific
385 responses to the abundant S and N proteins. The high population prevalence of CD4 responses
386 to M, NSP3 and ORF3A also agree with prior work (31). We also found responses to NSP2 and
387 ORF9B in at least half the subjects studied proteome-wide. NSP2 has previously been
388 described as a CD4 immunogen in convalescent persons, while ORF9B was not included in
389 some previous surveys (4, 11, 59-62). ORF9B is an alternative open reading frame within the
390 nucleoprotein locus encoding a 98 aa-long ORF9B protein that is abundant in infected cells
391 (54), localizes to mitochondria (63), elicits strong antibody responses (64), and is involved in
392 evasion of type I IFN responses (65). CD4 T cell breadth was studied in 17 samples from 8
393 persons. We found a median CD4 breadth of 7 viral antigens/specimen, and that 6 of 8 persons
394 recognized 7 or more proteins. In contrast, a survey of 99 convalescent persons with proteome-
395 wide peptides and an *ex vivo* AIM approach found an average of 3.2 CD4 T cell antigenic
396 proteins per person with no subject recognizing over 6 proteins (4).

397

398 TCL allowed tests of a large number of SARS-CoV-2 variant peptides. We found many
399 examples of abrogation or reduction of recognition of variants, some from variants of concern.
400 The literature consensus is that T cell responses to infection or vaccination are poly-specific,
401 such that failed variant epitope recognition may not have a net deleterious effect on immunity

402 (31). However, detailed investigations remain warranted. Tarke *et al.* tested PBMC from
403 convalescent persons infected early in the pandemic (66). While *ex vivo* T cell responses in
404 convalescent PBMC measured by AIM did not differ between ancestral- and variant-derived
405 peptide pools for CD4 or CD8 T cells, IFN- γ ELISPOT detected decreased overall for VOC
406 compared to Wu-1 peptides. Agerer *et al.* focused the HLA A*02:01-restricted response to the S
407 aa 269-277 YLQ epitope (67). The L270F variant showed decreased binding to HLA A*02:01
408 and no activation of YLQ-specific CD8 T cells. L270F has been detected in 3 of > 1.4 million
409 global sequences. In contrast, the P272L variant we investigated has been noted over 9000
410 times. aa 272 is modeled to face TCR (68) and to not reduce HLA A*02:01 binding. Based on
411 structural models (68) and other epitope variants (69, 70), the S P272L (epitope position 4) and
412 K417N or K417T (epitope position 1) variants studied herein could generate variant-specific T
413 cells, a hypothesis testable in convalescent PBMC. Recently, de Silva *et al.* documented
414 additional examples of strain-specific CD8 T cell recognition of SARS-CoV-2 variants (71).
415 COVID-19 vaccines mostly use Wu-1-like S antigen, such that vaccinee T cells may also detect
416 variant-specific T cell recognition. Recently, Keeton *et al.* detected modest differences in CD8 T
417 cell recognition of S between vaccine strain and delta variant peptides (72). In another vaccine
418 study (66), AIM responses to the B.1.351 S pool were lower for CD4 and CD8 T-cells compared
419 to Wu-1 peptides. The precise epitope and HLA restriction information in this report can focus
420 studies of variant recognition in cases of breakthrough infection as the pandemic continues to
421 evolve, and as epitope-based (NCT04776317) and variant-based vaccines (73) are studied in
422 clinical trials.

423
424 The present report also adds to the growing body of literature concerning cross-recognition of
425 sCoV and SARS-CoV-2 (20, 27, 74-76). The use of whole viral antigens in both stimulation and
426 readout stages of our investigations of sCoV allowed us to document that polyclonal CD4 TCL
427 from COVID-19 convalescent persons can recognize whole OC43 and 229E viral antigen. As

428 mentioned above, this assay format integrates antigen processing and presentation to
429 supplement studies that focus solely on peptide reactivity. Validation to the antigen, peptide,
430 and HLA restriction level was obtained for an epitope in OC43 S. The presence and sequencing
431 of SARS-CoV-2 and sCoV infections in our study population are unknown. However, the timing
432 of our specimen collection shortly after recovery from COVID-19, and sero-epidemiologic data
433 that most adults have been infected with multiple sCoV, suggest the T cell cross-reactivities we
434 detected may reflect prior sCoV infections boosted by SARS-CoV-2, Data concerning sCoV T
435 cell cross-reactivity can be integrated with antibody-based (77, 78) and clinical studies (79) to
436 determine if sCoV-specific immune memory modulate COVID-19 disease, and to guide
437 development of possible pan-coronavirus vaccines.

438

439 The current study has limitations. We observed no AIM response to whole SARS-CoV-2 in HD,
440 yet, several groups have documented the presence of SARS-CoV-2-reactive T cells in
441 uninfected individuals from either the naïve or sCoV-primed memory repertoires (20, 80). Our
442 approaches may be better suited to memory response to SARS-CoV-2 infection itself but could
443 be adapted to capture these responses, for example by using higher input cell numbers. We
444 noted only moderate preservation of TCR sequences comparing *ex vivo* sorted AIM (+) T cells
445 and expanded cultures. Biological factors related to TCR repertoire differences could include
446 rare clonotypes that assorted into either the *ex vivo* TCRseq or expansion fractions of the AIM
447 (+) cells, rather than being represented in both. Indeed, sequencing of AIM (+) cells *ex vivo*
448 shows broad and diverse responses at the TCR sequence level even to single epitopes, with
449 many clonotypes detected at low levels (81). T cell programming could render some T cells
450 refractory to expansion, with an exhausted T cell phenotype noted for SARS-CoV-2-specific
451 memory T cells in some settings (82). Technical factors could also contribute, ranging from DNA
452 extraction or PCR inefficiencies during TCR sequencing protocols to lack of provision of T cell
453 expansion culture conditions required for some of the AIM (+) cells. Analytically, we discounted

454 T cell clonotypes detected at less than two copies, potentially reducing concurrency between *ex*
455 *vivo* and expanded repertoires. Alternative methods such as single-cell TCRseq (83) to capture
456 the TCR repertoire AIM (+) cells *ex vivo* can be applied in the future to study the virus-specific
457 repertoire before and after expansion and to determine if there are transcriptional programs
458 correlated with failure to expand. In addition, a relatively low number of persons were studied.
459 The viral antigens used could have low abundance for some viral proteins in our antigen
460 preparation, leading to underestimation of antigen breadth.

461

462 In conclusion, T cells are a functionally important component of the specific acquired immune
463 response to SARS-CoV-2 infection and vaccination. We have shown brisk recognition of whole
464 SARS-CoV-2 by both CD4 and CD8 T cells from convalescent persons, provide estimates of the
465 integrated frequency of these cells in the circulation, and used proteome-covering tools to
466 approach within-subject antigenic breadth at the antigen and epitope levels. We found many
467 examples of loss of recognition of epitope variants by effector T cells recovered from persons
468 infected early in the pandemic, and used whole viral antigens to document coronavirus cross-
469 reactive T cell immunity.

470

471 **Methods**

472

473 **Subjects and specimens.** The COVID-19 cohort has been described (7-10). Subjects
474 reporting SARS-CoV-2 detection and an illness compatible with COVID-19 were recruited.
475 Subjects were seropositive for serum IgG for SARS-CoV-2 S and nucleoprotein (N) (7)
476 (Supplementary Table 1). PBMC were cryopreserved in liquid nitrogen. Adult healthy donor
477 (HD) PBMC were collected before 2019. Subjects provided informed written consent and
478 studies were Institutional Review Board-approved. HLA typing was by PCR amplicon
479 sequencing at Scisco Genetics (Seattle, WA).

480

481 **Antigens.** For whole viral antigen, SARS-CoV-2 strain Washington 1 (WA1) (84) (Genbank
482 MN985325.1) was cultured on Vero-E6 USAMRIID cells (gift of Dr. Ralph Baric, University of
483 North Carolina, Chapel Hill, NC) at MOI 0.1 for 48 hours to 80% cytopathic effect. Cells were
484 recovered by scraping and frozen/thawed thrice. Titers ranged from 4.2×10^7 to 4.8×10^8 pfu/ml
485 in Vero-E6-USAMRIID plaque assay (85) before inactivation. After UV light (900 mJ/cm^2) and
486 three cycles of freeze-thaw, plaque assays were negative on Vero-E6-USAMRIID. Vero mock
487 antigen was prepared in parallel. Full-length SARS-CoV-2 codon-optimized molecular clones
488 non-structural protein (NSP)1-NSP10, NSP12-NSP16, S, ORF3A, ORF3B, E, M, N, ORF6,
489 ORF7A, ORF7B, ORF8, N, ORF9B, ORF9C (also known as ORF9Bwu and ORF14) from
490 Wuhan-Hu-1 (Wu-1, Genbank NC_045512.2), and ORF10 from strain HKU-SZ-005b
491 (Genbank MN975262.1) cloned into pDONR207 or pDONR223 (29) (ThermoFisher, Waltham,
492 MA), were obtained from Addgene (Watertown, MA). Gateway™ reactions (ThermoFisher)
493 shuttled inserts to expression vectors pDEST103 and pDEST203 for CD8 and CD4 T cell
494 research (30). pDEST103 expresses proteins intracellularly as fusions after N-terminal eGFP
495 driven by a CMV promoter. pDEST203 expresses 6-histidine fusion proteins under the control of
496 a T7 promoter and is used (30) to express antigens via *in vitro* transcription/translation (IVTT)

497 (Expressway, ThermoFisher). SARS-CoV-2 S Wu-1 with the D614G mutation,
498 HDM_Spikedelta21_D614G (Addgene #158762), and isogenic mutant K417N are described
499 (86, 87). Additional plasmids were designed per S consensus data (22) (88) concordant with
500 representative sequences from GISAID (89) (EPI_ISL_760400 (B.1.1.7 lineage) and
501 EPI_ISL_700420 (B.1.351 lineage)). These were designed with the same 21 aa C-terminal
502 deletion as Wu-1 D614G and D614G/K417N and synthesized and cloned by Twist (South San
503 Francisco, CA) into pHDM to create HDM_Spikedelta21_B.1.351 and
504 HDM_Spikedelta21_B.1.1.7 for transient transfection of eukaryotic cells. The predicted
505 polypeptide sequences of strains WA1 used for PBMC stimulation, Wu-1 used for most peptides
506 differ at ORF8 aa 84 with an S residue in WA1 and L in Wu-1.

507

508 sCoV OC43 (NR-52725), 229E (NR-52726), and NL63 (NR-470) were obtained from BEI
509 Resources. OC43 was cultured on VERO E6 AT cells stably transduced with angiotensin
510 converting enzyme 2 (ACE2) and transmembrane serine protease 2 (gift from Michael S.
511 Diamond, Washington University, St. Louis, USA), 229E was cultured on Huh7 cells (90) and
512 NL63 cultured on MK2-LLC cells (CCL-7, ATCC). Antigen was prepared by freeze-thaw and
513 clarification (400 x g, 10 min, room temperature) of infected cells and UV-inactivated, with mock
514 uninfected cell antigens prepared in parallel. Viral titers measured in the producer cells prior to
515 UV were 1.6×10^5 TCID₅₀/ml (OC43), 2.3×10^6 TCID₅₀/ml (229E) and 2.0×10^2 TCID₅₀/ml
516 (NL63). Antigens were tested at 1:40 (v/v) in T cell assays. S genes from OC43, 229E, NL63
517 and HKU1 (R619-M89-303, R619-M66-303, R619-M90-303, R619-M91-303; 166014, 166015,
518 166016, 166017, all Addgene) were subcloned into pDEST203 (91). IVTT-expressed antigens
519 were tested at 1:1000.

520

521 Peptides covering the SARS-CoV-2 strain Wu-1 predicted proteome, 13 aa long overlapping by
522 9 aa, were obtained at $\geq 70\%$ purity (Genscript, Piscataway, NJ) and dissolved at 20 mg/ml in
523 DMSO (ThermoFisher). Peptides in SARS-CoV-2 ORFs polypeptides PP1a and PP1ab are
524 numbered by positions in the polypeptide rather than within non-structural proteins (NSPs).
525 Pools contained ≤ 54 peptides, maintaining 1 $\mu\text{g/ml}$ final in-assay concentrations each, and \leq
526 0.3% DMSO. Selected peptides containing variant aa, peptides shorter than 13 aa predicted to
527 bind to HLA class I alleles, or peptides internal to antigenic peptides were also studied. Variants
528 surveyed included variant 501Y.V1 lineage B.1.1.7 (alpha) (92), variant B501Y.V2 lineage
529 B.1.351 (beta) (22), variant 501Y.V3 P.1 lineage, (gamma) (93), and lineage B.1.617.2, (delta)
530 (nomenclature per US CDC Oct 2021 [https://www.cdc.gov/coronavirus/2019-](https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html#Interest)
531 [ncov/variants/variant-info.html#Interest](https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html#Interest)). sCoV homologs for defined SARS-CoV-2 Wu-1
532 epitopes in S, N, and M proteins were determined by sequence alignment. If ≥ 1 sCoV homolog,
533 amongst OC43, HKU1, 229E, and NL63, had identity at ≥ 7 aa with antigenic peptides from
534 SARS-CoV-2 Wu-1, 13 aa homologs of the antigenic SARS-CoV-2 peptide from all 4 sCoV
535 were assayed. In addition, OC43 S peptides, 15 aa long/11 aa overlap (EMPS-OC43-S-1, JPT,
536 Berlin, Germany) were tested as pools or single peptides at 1 $\mu\text{g/ml}$ final in $\leq 0.4\%$ DMSO.
537
538 **SARS-CoV-2-specific T cell enrichment and expansion.** For DC-AIM-based enrichment,
539 monocytes were enriched (CD14 positive, Stemcell) and cultured in serum-free AIM-V
540 (Stemcell) with 10 ng/ml each IL-4 and GM-CSF (R&D, Minneapolis, MN) in 6-well plates.
541 Monocyte-origin DC (moDC) were collected at day 7 with EDTA/scraping, and seeded at $2.5 \times$
542 10^5 /well in 48-well plates. SARS-CoV-2 antigen was loaded into moDC by adding 25 μl UV-
543 killed virus or mock antigen in 1 ml T cell medium (TCM). After 4 hours, 2×10^6 autologous total
544 T cells (negative selection, Stemcell) were added for 18 hours. Cells were stained with anti-
545 CD3-PE (BioLegend, UCHT1), anti-CD4-APC-Cy7 (Becton Dickinson, RPA-T4), anti-CD8-FITC
546 (ThermoFisher 3B5), anti-CD69-BV421 or PE-Cy7 (BioLegend, FN50), anti-CD137-APC

547 (Becton Dickinson, 4B4-1), and 7-actinomycin D (7-AAD). Live CD3⁺CD4⁺CD8⁻ or CD4⁻CD8⁺
548 cells with CD137 and CD69 expression were bulk-sorted and 20% of sorted cells were non-
549 specifically expanded for two cycles (94), with 80% saved for TCR sequencing. moDC were
550 also used to present single viral proteins. HeLa cells (CCL-2, ATCC) were transfected with
551 SARS-CoV-2 genes cloned into pDEST103, or pDEST103 control, using FuGene 6 (Promega)
552 and collected at 48 hours. Transfected cells were suspended to 1×10^6 cells/ml and UV-C-
553 treated in a 6-well plate with $3600 \mu\text{J}/\text{cm}^2$. moDC were collected at day 7 with EDTA and 1×10^5
554 moDC in 0.4 ml TCM were seeded into 48-well plates for 4 hours prior to adding 1×10^5 UV-
555 treated HeLa for one hour. 1.5×10^6 autologous PBMC in 0.1 ml were added at 37°C for 18
556 hours. AIM sorting was also used after stimulation of PBMC without moDC addition. For whole
557 virus, UV-inactivated SARS-CoV-2 was incubated at 1:20 to 1:40 dilution with 1.5×10^6 PBMC
558 in 0.2 ml TCM in 96 well U-bottom plates for 18 hours. Mock virus negative control and 1.6
559 $\mu\text{g}/\text{ml}$ phytohemagglutinin (PHA)-P (Remel, Lenexa, KS) positive control were included. For viral
560 proteins, SARS-CoV-2 individual ORFs in pDEST103 were transfected into and expressed by
561 COS-7 cells (#CRL-1651, ATCC, Manassas, VA), which were lysed with three cycles of freeze-
562 thaw treatment. Pooled lysates representing multiple SARS-CoV-2 proteins were added to
563 PBMC at a 1:1 volume ratio for 18 hours.

564

565 For proliferation-based enrichment, PBMC were labeled with cell-trace violet (CTV)
566 (ThermoFisher) and cultured at 4×10^6 /well in 24-well plates in 2 ml (TCM) (25) for 5 days with
567 SARS-CoV-2 peptide pools (≤ 54 peptides/pool, 1 $\mu\text{g}/\text{ml}$ final each) covering S (6 pools), M (one
568 pool), N (two pools), or NSP6 and E proteins (2 pools). After staining with anti-CD3-PE, anti-
569 CD4-APC (ThermoFisher, S3.5), anti-CD8-FITC, and 7-AAD for viability, live CD3⁺CTV^{low} cells
570 with CD4⁻CD8⁺ or CD4⁺CD8⁻ phenotype were bulk-sorted (FACSARIA II, Becton Dickinson).
571 Polyclonal CTV^{low} T cell lines were expanded twice polyclonally (94).

572

573 **Tetramer sorting.** Monomeric HLA-β2M complexes with UV-labile peptide (BioLegend) were
574 used for UV peptide exchange and tetramerized with streptavidin-APC or streptavidin-PE
575 (Becton Dickinson) per the manufacturer. Bulk-expanded CD8 T cells (~10⁶) were stained in
576 100 μl TCM with 2 μl tetramer for 30 minutes on ice, followed by anti-CD4-APC-H7 and anti-
577 CD8α-FITC. After 7-AAD staining, live CD8⁺CD4⁻tetramer^{high} cells were sorted, expanded (94),
578 and cryopreserved. CD8 T cells recognizing Merkel cell polyomavirus (MCPyV) T antigen (T-Ag)
579 aa 32-40/HLA A*03:01 were tetramer-sorted from Merkel cell carcinoma tumor-infiltrating
580 lymphocytes (28).

581

582 **T-cell functional assays.** CD8 TCL reactivity to viral proteins was measured using COS-7
583 artificial antigen presenting cells (aAPC) co-transfected with subject-specific HLA class I cDNA
584 and SARS-CoV-2 ORFs, or fragments of SARS-CoV-2 ORF1a/1ab (95). HLA A and B cDNA
585 alleles were amplified by RT-PCR (94) or synthesized (Genscript), cloned into pcDNA3.1(-)
586 (ThermoFisher) (96) and sequence-verified. COS-7 in 96-well flat plates were co-transfected
587 with 100 ng/well each HLA cDNA and SARS-CoV-2-p103 plasmids, using FuGene6 (96). After
588 2 days, 1 x 10⁵ CD8 TCL/well were added for 24-48 hours into 200 μl TCM, and secreted IFN-
589 gamma (IFN-γ) measured by ELISA (96). For CD8 T cell responses to peptides, aAPC
590 expressed HLA cDNA only. At 2 days, 1-10 μg/ml viral peptide or DMSO control was added with
591 responder TCL, or aAPC were peptide-pulsed for 1 hour at 37 °C, 5% CO₂ and washed prior to
592 adding TCL. Alternatively, peptide specificity assays used autologous EBV-lymphocyte
593 continuous line (EBV-LCL) as APC at 2-5 x 10⁴ cells/well in 96-well U-bottom plates, in duplicate
594 or triplicate, with 5-10 x 10⁵ CD8 TCL responders/well. Single or pooled peptides were added at
595 1 μg/ml each final in ≤ 0.3% DMSO. For a peptide to be listed as a CD8 T cell epitope, we
596 required recognition (IFN-γ OD₄₅₀ > 2X DMSO control) of 1 μg/ml or less peptide in ≥ 2
597 independent assays. To measure CD8 T cell recognition of SARS-CoV-2-infected cells, human
598 bronchial epithelial cell 3 immortalized with cyclin dependent kinase 4 and human telomerase

599 reverse transcriptase (HBEC3-KT) (97) transduced with ACE2 (44) (HBE3-KT-A) were infected
600 at MOI 2 in 6-well plates using strain WA1-GFP (gift of Dr. Ralph Baric), or mock-infected, for 24
601 hours, harvested with Accutase (Thermo-Fisher) and plated at 20,000 cells/well in 96 well U-
602 bottom plates. CD8 T cells were added (100,000/well) to a final volume of 200 μ l TCM.
603 Supernatants after 24 hours were assayed by IFN- γ ELISA (98).

604
605 CD4 T cell assays for whole virus and IVTT proteins used PBMC as APC. In duplicate or
606 triplicate 96-well U-bottoms, 5-10 x 10⁴ each autologous PBMC and CD4 TCL were seeded in
607 200 μ l TCM, with whole UV-treated SARS-CoV-2 or mock antigen (1:20-1:40), IVTT
608 preparations (1:1000-1:2000) from SARS-CoV-2 or empty vector or HSV-2 gene-containing (99)
609 negative controls, single or pooled peptides or DMSO control, or PHA-P (1.6 μ g/ml) positive
610 control. T cell activation was determined by supernatant IFN- γ by ELISA at 1-2 days or ³H
611 thymidine incorporation (proliferation assay at day 3-day 4 (100). When proliferation was
612 measured, autologous PBMC were irradiated (3,300 rad, X-ray source). The criteria for positivity
613 were that in duplicate assays, both raw CPM values were at least twice the average of the
614 negative control wells containing irrelevant HSV antigens and media.

615
616 Alternatively, responses to whole virus and IVTT proteins were measured by intracellular
617 cytokine secretion (ICS). Polyclonal CD4 TCL were CTV-labeled (25). Autologous PBMC and
618 CD4 TCL (2-5 x 10⁵ each) were co-incubated in 200 μ l TCM in 96-well U-bottoms with antigens
619 or controls at concentrations listed above. Co-stimulatory mAbs (anti-CD28 and anti-CD49d,
620 BioLegend) and Brefeldin A were added (25) and cells analyzed after 16-18 hours. Cells were
621 stained with Near-IR live/dead (ThermoFisher), lysed with 1X FACS lysing solution (Becton
622 Dickinson), permeabilization with FACS Perm 2 (Becton Dickinson), and stained with anti-CD3-
623 PE, anti-CD4-FITC (ThermoFisher, S3.5), and anti-CD8-PerCP5.5 (SK1), anti-IFN- γ -PE-Cy7,
624 (B27, Becton Dickson) and anti-IL-2 (MQ1-17H12, Becton Dickinson). Data were acquired with

625 FACSCANTO and cytokine expression quantified for live, CTV-positive CD3⁺CD4⁺CD8⁻ single
626 cells (FlowJo 10.7.1, Becton Dickinson). For ICS-based proteome screens of CD4 TCL, two
627 criteria were both required to score a protein positive. The ratio of the percent of IFN- γ and/or
628 IL-2 positive CD4 T cells with SARS-CoV-2 antigen compared with pDEST203 empty vector-
629 derived IVTT product, was > 2. For subjects W002 and W011 with high IFN- γ background for
630 pDEST203 empty vector, the percent of double-positive IFN- γ /IL-2 cells, only, was used.
631 Second, the difference in cytokine-positive cells between a SARS-CoV-2 protein and empty
632 vector was > 1%.

633
634 CD4 T cell peptide analyses used autologous EBV-LCL as APC. TCL (2-5 x 10⁴/well) and EBV-
635 LCL (5-20 X 10³/well) were co-plated in 96-well U plates in duplicate or triplicate in 200 μ l TCM.
636 Peptides at 1 μ g/ml each final concentration were added as pools or singletons in \leq 0.3%
637 DMSO, or DMSO negative control. After 1 to 2 days, supernatant IFN- γ was measured by
638 ELISA. For some assays with high IFN- γ ELISA OD₄₅₀ values for negative control stimuli, ELISA
639 was performed with diluted supernatants. In order for a peptide to be reported as an epitope,
640 two or more wells tested with 1 μ g/ml peptide were required to have an IFN- γ OD₄₅₀ at least
641 twice above DMSO background in at least two assays. For proliferation assays, peptides (1
642 μ g/ml) were tested using autologous EBV-LCL (1 X 10⁴/well, irradiated 10,000 rad) and
643 responder TCL (5 X 10⁴/well) in duplicate. For a peptide to be reported as an epitope, both
644 replicates had a count per minute (CPM) value more than 2-fold the average CPM of DMSO
645 negative controls, and, in follow-up triplicate screens, at least two of the three CPM values were
646 more than 2-fold average CPM of negative controls. To enumerate CD4 T cell reactivities per-
647 subject, each reactive peptide was counted as a separate epitope. If two variant SARS-CoV-2
648 peptides were reactive for the same person, this was counted as one reactivity. Reactivities
649 detected in more than one workflow or PBMC timepoint per person are counted once.

650 Responses to the same or variant peptides in multiple participants were analyzed both
651 separately and after collapse to unique peptides.

652

653 We defined CD4 TCL HLA restriction as published (40). First, serial dilutions of peptide (1, 0.1,
654 or 0.01 $\mu\text{g/ml}$) were tested in triplicate using autologous EBV-LCL as APC without or with mAbs
655 that block HLA DR, DP, or DQ (100). To determine allele-level restriction, engineered APC
656 expressing single HLA class II heterodimers were selected (40) to match the study subject.
657 Negative controls were cells parental to the single antigen line (SAL). SAL assays typically used
658 1 $\mu\text{g/ml}$ peptide or DMSO control. Some used SAL washed after a 1-hour pulse at 37 °C with
659 peptides in titration. CD4 TCL were added and IFN- γ secretion measured by ELISA. To
660 estimate functional avidity, we set an index value of 100% to the difference between the mean
661 IFN- γ OD₄₅₀ values of 1 $\mu\text{g/ml}$ peptide and of DMSO. A peptide concentration was scored as
662 positive if at least two of three triplicates at that concentration yielded net IFN- γ OD₄₅₀ values
663 (raw values minus the mean of DMSO) at least 30% of this index value. For selected peptide
664 epitopes an alternative or expanded dilution series was used.

665

666 **TCR sequencing and analysis.** AIM (+) PBMC were flash frozen after sorting in a minimal
667 volume of TCM and DNA manually isolated with the Qiagen blood kit for small samples. DNA
668 from culture-expanded AIM (+) cells was isolated by Adaptive. T cell receptor beta (*TRB*)
669 complementarity determining region 3 (CDR3) repertoire sequencing was performed at Adaptive
670 Biotechnologies (Seattle, WA) using the Immunoseq™ TCRBv4b platform. Two replicate DNA
671 aliquots were processed in parallel and only productive TRB CDR3 gene rearrangements
672 present in at least one read in both replicates were reported. Analyses focused on functional
673 CDR3 amino acid identity.

674

675 **Data availability.** T cell epitopes have been uploaded to IEDB(102) with accession numbers
676 1000861 and 1000866. TCR datasets are in ImmuneACCESS (Adaptive).

677

678 **Approval.** By the University of Washington Institutional Review Board as Study00004312.

679

680 **Statistics and variant abundance.** Proportions of *ex vivo* AIM (+) cells were compared within-
681 person between mock and stimulated conditions using Wilcoxon matched-pairs signed-ranks
682 test (Instat 3.10, GraphPad, San Diego, CA). Proportions of *ex vivo* AIM (+) cells after
683 stimulation were compared between clinical cohorts using Mann-Whitney test. P values are two-
684 tailed. Correlation between IFN- γ and proliferation results used linear regression and default
685 parameters (Prism 9.1.0, GraphPad). To estimate the global prevalence of SARS-CoV-2 amino
686 acid variants, the worldwide SARS-CoV-2 sequence dataset hosted at GISAID (89) was
687 accessed (101) using the mutation details routine, while lineages containing specific mutations
688 were queried via Nextstrain (23), which accesses a representative subset of GISAID.

689

690

691 Table 1. Summary of varied T cell recognition of SARS-CoV-2 peptides from strain Wu-1 and variants.

T cell phenotype	HLA restriction ¹	protein	peptide ²	Wu-1 ³	variant	variant recognition ⁴	predicted HLA binding effect ⁵	PANGO lineage(s) ⁶	prevalence ⁷
CD4	DR	S	37-49	YYPDKVFRSSVLH	H49Y	reduced	not applicable	B.1, others	0.19%
CD4	DRB1*07:01, DRB1*15:01	S	61-73	NVTWFHAIHVSGT	del69-70	not detected	moderate decrement *07:01; large decrement *15:01	B.1.1.7	23.76%
CD4	DRB1*11:01	S	61-73	NVTWFHAIHVSGT	del69-70	not detected	large decrement	B.1.1.7	23.76%
CD4	DP, likely A1*01:03/B1*04:01	S	133-145	FQFCNDPFLGVYY	D138Y	reduced	no effect	B.1.351	2.46%
CD4	DP, likely A1*01:03/B1*04:01	S	133-145	FQFCNDPFLGVYY	G142D	reduced	no effect	B.1.617.2	28.77%
CD4	DP, likely A1*01:03/B1*04:01	S	133-145	FQFCNDPFLGVYY	Y144del	reduced	moderate decrement	B.1.1.7	23.46%
CD4	DP, likely A1*01:03/B1*04:01	S	165-177	NCTFEYVSQPFLM	L176F	reduced, not detected	no effect	multiple	0.19%
CD4	DR	S	165-177	NCTFEYVSQPFLM	L176F	reduced	not applicable	multiple	0.19%
CD4	DR ⁸	S	209-221	PINLVRDLPQGFS	D215H	not detected	no effect	multiple	0.08%
CD4	DR ⁸	S	209-221	PINLVRDLPQGFS	D215G	not detected	moderate/large decrement	B.1.351	0.78%
CD4	DR	S	233-245	INTRFQTLALH	del242-244	not detected	no effect/moderate decrement	B.1.351	0.75%
CD8	A*02:01	S	269-277	YLQPRTFLL	P272L	not detected	no effect	B.1.177	0.23%
CD8	A*03:01	S	378-386	KCYGVSPK	K378N	not detected	moderate decrement	n/a	0.01%
CD8	A*02:01	S	417-425	KIADYNYKL	K417N	not detected	no effect	B.1.351	0.93%
CD8	A*02:01	S	417-425	KIADYNYKL	K417T	not detected	no effect	P.1	2.26%
CD4	DR	S	485-497	GFNCYEPLQSYGF	F490S	not detected	not applicable	multiple	0.29%
CD8	A*29:02	S	489-497	YEPLQSYGF	F490S	not detected	moderate decrement	multiple	0.29%
CD4	unknown	S	665-677	PIGAGICASYQTQ	Q677H	increased	not applicable	multiple	1.10%
CD4	unknown	S	693-705	IAYTMSLGAENSV	A701V	reduced	no effect	B.1.351	1.59%
CD4	DRB1*07:01; DRB1*04:07/DRB4*01:03 ⁹	S	717-729	NFTISVITEILPV	T723I	reduced	moderate decrement	B.1.389	0.03%
CD4	DR	S	973-985	ISSVLNDILSRDL	S982A	not detected	not applicable	B.1.1.7	23.81%

CD4	DR	S	1017-1029	EIRASANLAAIKM	T1027I	reduced	no effect	P.1	2.53%
CD4	DRB1*03:01	S	1113-1125	QIITDNTFVSGN	D1118H	not detected	large decrement	B.1.1.7	23.81%
CD4	DQ	N	13-25	PRITFGGPSDSTG	P13L	reduced	not applicable	B.6.8, B.1.1.1, others	0.69%
CD4	DR	N	217-229	AALALLLDRLNQ	A220V	neutral	not applicable	B.1.177.72, others	3.62%
CD4	unknown	N	201-213	SSRGTSPARMAGN	203/204	not detected		multiple	30.07%
CD4	unknown	NSP6	3601-3613	SLFFFLYENAFPL	L3606F	not detected	not applicable	B.6.8, many others	2.48%
CD4	unknown	ORF3A	241-253	EEHVQIHTIDGSS	G251V	not detected	not applicable	multiple	0.16%
CD8	A*11:01	M	169-181	TVATSRILSYKYL	T175M	not detected	no effect	B.1.1	0.05%

692

693

694 ¹ Restricting locus for CD8 T cells proven using aAPC, and available information for CD4 T cells using locus-blocking mAbs and/or
695 SAL.

696 ² Amino acid number in protein in SARS-CoV-2 strain Wu-1 proteome. For NSP6, position in ORF1ab polypeptide.

697 ³ Amino acid sequence in SARS-CpoV-2 strain Wu-1.

698 ⁴ Summary of experimental data in this report. If differing effects are seen for > 1 participants' T cells, both results are listed. Not
699 detected signifies >90% reduction in mean net IFN- γ OD₄₅₀ at 1 μ g/ml peptide.

700 ⁵ Summary of predicted HLA binding to implicated HLA restricting allele, if determined, from consensus algorithms at
701 <http://tools.iedb.org/main/tcell/>

702 ⁶ Derived from representative sampling of ~ 3500 worldwide complete sequences at <https://nextstrain.org/> accessed Nov 2021.

703 Lineages include B.1.1.7, also known as alpha, B.1.351, also known as beta, B.1.617.2, also known as delta, P.1, also known as
704 gamma.

705 ⁷ Worldwide cumulative prevalence at https://covid19dashboard.regeneron.com/?tab=Mutation_Details accessed Nov 2021.

706 ⁸ DRB1*03:01 in one subject, DR locus in 2nd subject.

707 ⁹ Responses in one subject DRB1*07:01 restricted; in 2nd subject restricted by both alleles shown; significantly reduced recognition

708 of variant for both subjects using autologous EBV-LCL as APC.

709 **Figure legends**

710

711 Fig. 1. AIM detection and enrichment of SARS-CoV-2 specific T cells in response to whole virus.

712 A: PBMC from participant W003 incubated with inactivated cell-associated SARS-CoV-2 or

713 mock antigen. Gating scheme at top. Lower panels show expression of activation markers

714 CD137 and CD69 in response to 18 hour stimulation amongst CD4 or CD8 T cells. B: Similar

715 layout for subject W005, specimen 1 PBMC stimulated with autologous moDC pre-treated with

716 SARS-CoV-2 or mock antigen. Gating scheme at top. For both stimulation methods, numbers

717 are percentages of gated T cells expressing dual activation markers. C: CD69/CD137 positive

718 CD4 T cells from the pathway in part A: were expanded and tested for reactivity with inactivated

719 cell-associated SARS-CoV-2 or mock antigen. Gated, live, responder, CD3+/CD4+/CD8-cells

720 are shown. Numbers are percent of cells accumulating the indicated cytokines.

721

722 Fig. 2. Recognition of infected respiratory epithelial cells by SARS-CoV-2-specific CD8

723 T cells. A: HBEC3-KT-A cells with or without infection with SARS-CoV-2 were co-

724 cultivated with tetramer-enriched, HLA A*03:01-restricted, S 378-386-specific CD8 T

725 cells and activation measured by IFN- γ secretion. S: S-specific T cells. M: control

726 MCPyV-specific CD8 T cells. B: Both T cell populations specifically recognized HBEC3-

727 KT-A cells treated with relevant viral peptide.

728

729 Fig. 3. SARS-CoV-2 CD8 T cell antigens and epitopes from PBMC stimulation with whole

730 SARS-CoV-2 antigen. A: Subject W005, specimen 1 CD8 TCL were assayed with aAPC

731 expressing each SARS-CoV-2 protein and relevant HLA A and B. Four reactivities were noted.

732 B: Subject W010 CD8 TCL is reactive with HLA A*01:01 aAPC co-transfected with NSP3. For A:

733 and B: negative controls at right. C: CD8 TCL from B: assayed against column (C) and row (R)

734 pooled NSP3 peptides with autologous EBV-LCL as APC. D: Tetramer stain of CD8 TCL before

735 and after sorting and expansion of tetramer-positive cells. Percentages of tetramer-positive cells
736 shown E: Reactivity of tetramer-enriched cells for aAPC transfected with the indicated plasmids
737 or treated with the indicated peptides. F: Dose-response for HLA A*01:01 aAPC with the
738 indicated concentrations of NSP3 1637-1646. Duplicate or triplicate IFN- γ release assays show
739 raw data as bars (A) or dots for each value and means as bars (B, C, E, F).

740

741 Fig. 4. Summary of SARS-CoV-2 proteome-level T cell reactivity for PBMC after COVID-19
742 illness, using AIM enrichment with whole viral antigen. Rows indicate donors and days between
743 recovery from illness and PBMC sampling. Upper 5 rows were studied without DC boosting;
744 lower 12 rows used this procedure. Columns are individual SARS-CoV-2 proteins. A: CD8 TCL
745 scoring positive (purple). B: CD4 TCL scoring positive (red). At right are number of proteins
746 recognized and at bottom are number of subjects with reactivity at one or more time points.

747

748 Fig. 5. A: CD4 TCL from PBMC stimulated with moDC and whole SARS-CoV-2 (subjects W001,
749 W005, W012) or PBMC stimulated with whole SARS-CoV-2 (subject W003) recognize whole
750 SARS-CoV-2, and sCoVOC43 or 229E antigens (V), but not mock (M) antigens. B: CD4 TCL
751 from subject W001 recognizes full-length S protein from OC43 but not empty vector control. C:
752 CD4 TCL recognize homologous S peptides from SARS-CoV-2 and OC43 in an HLA DR-
753 restricted fashion as indicated by inhibition with locus-specific mAb. An overlapping SARS-CoV-
754 2 peptide shows DRB1*15:01 restriction at right. Conserved AA are underlined.

755

756 Fig. 6. CD8 TCL recognition by SARS-CoV-2 variant peptides. aAPC transfected with HLA
757 A*02:01 and treated with wild-type but not variant peptides were recognized by polyclonal CD8
758 TCL lines. Lineage B.1.351 is also known as beta and P.1 is also known as gamma).

759

760 Fig. 7. CD4 TCL recognition by SARS-CoV-2 variant peptides. Summary of recognition of S
761 strain Wu-1 peptides and variants. Donors indicated at top. Each Wu-1 peptide recognized by
762 one or more subject is numbered at left. Coordinates and AA substitutions or deletions of
763 variants tested are listed at right. Variants in WHO VOC indicated with blue square. Color codes
764 at left summarize level of recognition of variant peptide by each TCL. VBM = variants being
765 monitored, VOC = variants of concern per US CDC October 2021.

767 **References**

768

- 769 1. Hansen CH, Michlmayr D, Gubbels SM, Mølbak K, and Ethelberg S. Assessment of protection
770 against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020:
771 a population-level observational study. *Lancet (London, England)*. 2021.
772 2. Topol EJ. Messenger RNA vaccines against SARS-CoV-2. *Cell*. 2021;184(6):1401.
773 3. McMahan K, Yu J, Mercado NB, Loos C, Tostanoski LH, Chandrashekar A, et al. Correlates of
774 protection against SARS-CoV-2 in rhesus macaques. *Nature*. 2021;590(7847):630-4.
775 4. Tarke A, Sidney J, Kidd CK, Dan JM, Ramirez SI, Yu ED, et al. Comprehensive analysis of T cell
776 immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. *Cell*
777 *reports Medicine*. 2021;2(2):100204.
778 5. Snyder TM, Gittelman RM, Klinger M, May DH, Osborne EJ, Taniguchi R, et al. Magnitude and
779 Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population
780 Levels. *medRxiv*. 2020.
781 6. Braun J, Loyal L, Frentsch M, Wendisch D, Georg P, Kurth F, et al. SARS-CoV-2-reactive T cells in
782 healthy donors and patients with COVID-19. *Nature*. 2020;587(7833):270-4.
783 7. Boonyaratanakornkit J, Morishima C, Selke S, Zamora D, McGuffin S, Shapiro AE, et al. Clinical,
784 laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among
785 COVID-19 convalescent plasma donor candidates. *The Journal of clinical investigation*.
786 2021;131(3).
787 8. Yu KK, Fischinger S, Smith MT, Atyeo C, Cizmeci D, Wolf CR, et al. Comorbid illnesses are
788 associated with altered adaptive immune responses to SARS-CoV-2. *JCI Insight*. 2021.
789 9. Elyanow R, Snyder TM, Dalai SC, Gittelman RM, Boonyaratanakornkit J, Wald A, et al. T-cell
790 receptor sequencing identifies prior SARS-CoV-2 infection and correlates with neutralizing
791 antibody titers and disease severity. *medRxiv : the preprint server for health sciences*.
792 2021:2021.03.19.21251426. In Revision, Journal of Clinical Investigation.
793 10. Phan IQ, Subramanian S, Kim D, Murphy M, Pettie D, Carter L, et al. In silico detection of SARS-
794 CoV-2 specific B-cell epitopes and validation in ELISA for serological diagnosis of COVID-19.
795 *Scientific reports*. 2021;11(1):4290.
796 11. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of T Cell
797 Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed
798 Individuals. *Cell*. 2020;181(7):1489-501.e15.
799 12. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-
800 CoV-2 assessed for up to eight months after infection. *bioRxiv : the preprint server for biology*.
801 2020.
802 13. Clute SC, Naumov YN, Watkin LB, Aslan N, Sullivan JL, Thorley-Lawson DA, et al. Broad cross-
803 reactive TCR repertoires recognizing dissimilar Epstein-Barr and influenza A virus epitopes. *J*
804 *Immunol*. 2010;185(11):6753-64.
805 14. Vuorela A, Freitag TL, Leskinen K, Pessa H, Härkönen T, Stracenski I, et al. Enhanced influenza A
806 H1N1 T cell epitope recognition and cross-reactivity to protein-O-mannosyltransferase 1 in
807 Pandemrix-associated narcolepsy type 1. *Nature communications*. 2021;12(1):2283.
808 15. Chiou SH, Tseng D, Reuben A, Mallajosyula V, Molina IS, Conley S, et al. Global analysis of shared
809 T cell specificities in human non-small cell lung cancer enables HLA inference and antigen
810 discovery. *Immunity*. 2021;54(3):586-602.e8.
811 16. Huisman W, Lebox DAT, van der Maarel LE, Hageman L, Amsen D, Falkenburg JHF, et al.
812 Magnitude of Off-Target Allo-HLA Reactivity by Third-Party Donor-Derived Virus-Specific T Cells
813 Is Dictated by HLA-Restriction. *Frontiers in immunology*. 2021;12:630440.

- 814 17. Koelle DM, Chen HB, McClurkan CM, and Petersdorf EW. Herpes simplex virus type 2-specific
815 CD8 cytotoxic T lymphocyte cross-reactivity against prevalent HLA class I alleles. *Blood*.
816 2002;99(10):3844-7.
- 817 18. Hammer GE, Kanaseki T, and Shastri N. The final touches make perfect the peptide-MHC class I
818 repertoire. *Immunity*. 2007;26(4):397-406.
- 819 19. Starck SR, and Shastri N. Nowhere to hide: unconventional translation yields cryptic peptides for
820 immune surveillance. *Immunological reviews*. 2016;272(1):8-16.
- 821 20. Lineburg KE, Grant EJ, Swaminathan S, Chatzileontiadou DSM, Szeto C, Sloane H, et al. CD8(+)
822 T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope cross-react with
823 selective seasonal coronaviruses. *Immunity*. 2021;54(5):1055-65.e5.
- 824 21. McCarthy KR, Rennick LJ, Nambulli S, Robinson-McCarthy LR, Bain WG, Haidar G, et al. Recurrent
825 deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape. *Science (New York, NY)*.
826 2021;371(6534):1139-42.
- 827 22. Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, et al. Emergence of a
828 SARS-CoV-2 variant of concern with mutations in spike glycoprotein. *Nature*. 2021.
- 829 23. Hadfield J, Megill C, Bell SM, Huddleston J, Potter B, Callender C, et al. Nextstrain: real-time
830 tracking of pathogen evolution. *Bioinformatics (Oxford, England)*. 2018;34(23):4121-3.
- 831 24. Bouhaddou M, Memon D, Meyer B, White KM, Rezelj VV, Correa Marrero M, et al. The Global
832 Phosphorylation Landscape of SARS-CoV-2 Infection. *Cell*. 2020;182(3):685-712.e19.
- 833 25. Hanson DJ, Tsvetkova O, Rerolle GF, Greninger AL, Sette A, Jing L, et al. Genome-Wide Approach
834 to the CD4 T-Cell Response to Human Herpesvirus 6B. *J Virol*. 2019;93(14).
- 835 26. DeWitt WS, Emerson RO, Lindau P, Vignali M, Snyder TM, Desmarais C, et al. Dynamics of the
836 cytotoxic T cell response to a model of acute viral infection. *J Virol*. 2015;89(8):4517-26.
- 837 27. Ferretti AP, Kula T, Wang Y, Nguyen DMV, Weinheimer A, Dunlap GS, et al. Unbiased Screens
838 Show CD8(+) T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely
839 Reside outside the Spike Protein. *Immunity*. 2020;53(5):1095-107.e3.
- 840 28. Jing L, Ott M, Church CD, Kulikauskas RM, Ibrani D, Iyer JG, et al. Prevalent and Diverse
841 Intratumoral Oncoprotein-Specific CD8(+) T Cells within Polyomavirus-Driven Merkel Cell
842 Carcinomas. *Cancer immunology research*. 2020;8(5):648-59.
- 843 29. Kim DK, Knapp JJ, Kuang D, Chawla A, Cassonnet P, Lee H, et al. A Comprehensive, Flexible
844 Collection of SARS-CoV-2 Coding Regions. *G3 (Bethesda, Md)*. 2020;10(9):3399-402.
- 845 30. Jing L, Haas, J., Chong, T.M., Bruckner, J.J., Dann, G.C., Dong, L., Marshak, J.O., McClurkan, C.L.,
846 Yamamoto, T.N., Bailer, S.M., Laing, K.J., Wald, A., Verjans, G.M.G.M., Koelle, D.M. Herpes
847 simplex virus type 1 T-cells antigens in humans revealed by cross-presentation and genome-
848 wide screening. *Journal of Clinical Investigation*. 2012;122:654-73.
- 849 31. Sette A, and Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. *Cell*. 2021;184(4):861-
850 80.
- 851 32. Le Bert N, Clapham HE, Tan AT, Chia WN, Tham CYL, Lim JM, et al. Highly functional virus-specific
852 cellular immune response in asymptomatic SARS-CoV-2 infection. *J Exp Med*. 2021;218(5).
- 853 33. Wyllie D, Jones HE, Mulchandani R, Trickey A, Taylor-Phillips S, Brooks T, et al. SARS-CoV-2
854 responsive T cell numbers and anti-Spike IgG levels are both associated with protection from
855 COVID-19: A prospective cohort study in keyworkers. *medRxiv*. 2021:2020.11.02.20222778.
- 856 34. Van Damme KFA, Tavernier S, Van Roy N, De Leeuw E, Declercq J, Bosteels C, et al. Case Report:
857 Convalescent Plasma, a Targeted Therapy for Patients with CVID and Severe COVID-19. *Frontiers*
858 *in immunology*. 2020;11:596761.
- 859 35. Tarhini H, Reicoing A, Bridier-Nahmias A, Rahi M, Lambert C, Martres P, et al. Long term SARS-
860 CoV-2 infectiousness among three immunocompromised patients: from prolonged viral
861 shedding to SARS-CoV-2 superinfection. *The Journal of infectious diseases*. 2021.

- 862 36. Shaan Lakshmanappa Y, Elizaldi SR, Roh JW, Schmidt BA, Carroll TD, Weaver KD, et al. SARS-CoV-
863 2 induces robust germinal center CD4 T follicular helper cell responses in rhesus macaques.
864 *Nature communications*. 2021;12(1):541.
- 865 37. Blum JS, Wearsch PA, and Cresswell P. Pathways of antigen processing. *Annual review of*
866 *immunology*. 2013;31:443-73.
- 867 38. Matyushenko V, Isakova-Sivak I, Kudryavtsev I, Goshina A, Chistyakova A, Stepanova E, et al.
868 Detection of IFN γ -Secreting CD4(+) and CD8(+) Memory T Cells in COVID-19 Convalescents
869 after Stimulation of Peripheral Blood Mononuclear Cells with Live SARS-CoV-2. *Viruses*.
870 2021;13(8).
- 871 39. Jing L, Schiffer JT, Chong TM, Bruckner JJ, Davies DH, Felgner PL, et al. CD4 T-cell memory
872 responses to viral infections of humans show pronounced immunodominance independent of
873 duration or viral persistence. *J Virol*. 2013;87(5):2617-27.
- 874 40. Campbell VL, Nguyen L, Snoey E, McClurkan CL, Laing KJ, Dong L, et al. Proteome-Wide Zika Virus
875 CD4 T Cell Epitope and HLA Restriction Determination. *Immunohorizons*. 2020;4(8):444-53.
- 876 41. Nayak K, Jing L, Russell RM, Davies DH, Hermanson G, Molina DM, et al. Identification of novel
877 Mycobacterium tuberculosis CD4 T-cell antigens via high throughput proteome screening.
878 *Tuberculosis (Edinb)*. 2015;95(3):275-87.
- 879 42. Laing KJ, Russell RM, Dong L, Schmid DS, Stern M, Magaret A, et al. Zoster vaccination increases
880 the breadth of CD4+ T cells responsive to varicella zoster virus. *The Journal of infectious*
881 *diseases*. 2015.
- 882 43. Diao B, Wang C, Wang R, Feng Z, Zhang J, Yang H, et al. Human kidney is a target for novel
883 severe acute respiratory syndrome coronavirus 2 infection. *Nature communications*.
884 2021;12(1):2506.
- 885 44. Addetia A, Lieberman NAP, Phung Q, Hsiang TY, Xie H, Roychoudhury P, et al. SARS-CoV-2 ORF6
886 Disrupts Bidirectional Nucleocytoplasmic Transport through Interactions with Rae1 and Nup98.
887 *mBio*. 2021;12(2).
- 888 45. Akilesh S, Nicosia RF, Alpers CE, Tretiakova M, Hsiang TY, Gale M, Jr., et al. Characterizing Viral
889 Infection by Electron Microscopy: Lessons from the Coronavirus Disease 2019 Pandemic. *The*
890 *American journal of pathology*. 2021;191(2):222-7.
- 891 46. Lodes N, Seidensticker K, Perniss A, Nietzer S, Oberwinkler H, May T, et al. Investigation on
892 Ciliary Functionality of Different Airway Epithelial Cell Lines in Three-Dimensional Cell Culture.
893 *Tissue engineering Part A*. 2020;26(7-8):432-40.
- 894 47. Ahn JH, Kim J, Hong SP, Choi SY, Yang MJ, Ju YS, et al. Nasal ciliated cells are primary targets for
895 SARS-CoV-2 replication in the early stage of COVID-19. *The Journal of clinical investigation*.
896 2021;131(13).
- 897 48. Zhang Y, Chen Y, Li Y, Huang F, Luo B, Yuan Y, et al. The ORF8 protein of SARS-CoV-2 mediates
898 immune evasion through down-regulating MHC-I. *Proceedings of the National Academy of*
899 *Sciences of the United States of America*. 2021;118(23).
- 900 49. Wagner Klea. Recruitment of highly functional SARS-CoV-2-specific CD8+ T cell receptors
901 mediating cytotoxicity of virus-infected target cells in non-severe COVID-19. 2021.
- 902 50. Koelle DM, Tigges MA, Burke RL, Symington FW, Riddell SR, Abbo H, et al. Herpes simplex virus
903 infection of human fibroblasts and keratinocytes inhibits recognition by cloned CD8+ cytotoxic T
904 lymphocytes. *Journal of Clinical Investigation*. 1993;91:961-8.
- 905 51. Kaneko N, Boucau J, Kuo HH, Perugino C, Mahajan VS, Farmer JR, et al. Expansion of Cytotoxic
906 CD4+ T cells in the lungs in severe COVID-19. *medRxiv*. 2021.
- 907 52. Meckiff BJ, Ramirez-Suastegui C, Fajardo V, Chee SJ, Kusnadi A, Simon H, et al. Imbalance of
908 Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4(+) T Cells in COVID-19. *Cell*.
909 2020;183(5):1340-53 e16.

- 910 53. Ramos da Silva S, Ju E, Meng W, Paniz Mondolfi AE, Dacic S, Green A, et al. Broad Severe Acute
911 Respiratory Syndrome Coronavirus 2 Cell Tropism and Immunopathology in Lung Tissues From
912 Fatal Coronavirus Disease 2019. *The Journal of infectious diseases*. 2021;223(11):1842-54.
- 913 54. Bojkova D, Klann K, Koch B, Widera M, Krause D, Ciesek S, et al. Proteomics of SARS-CoV-2-
914 infected host cells reveals therapy targets. *Nature*. 2020;583(7816):469-72.
- 915 55. Davidson AD, Williamson MK, Lewis S, Shoemark D, Carroll MW, Heesom KJ, et al.
916 Characterisation of the transcriptome and proteome of SARS-CoV-2 reveals a cell passage
917 induced in-frame deletion of the furin-like cleavage site from the spike glycoprotein. *Genome
918 medicine*. 2020;12(1):68.
- 919 56. Ihling C, Tänzler D, Hagemann S, Kehlen A, Hüttelmaier S, Arlt C, et al. Mass Spectrometric
920 Identification of SARS-CoV-2 Proteins from Gargle Solution Samples of COVID-19 Patients.
921 *Journal of proteome research*. 2020;19(11):4389-92.
- 922 57. Nikolaev EN, Indeykina MI, Brzhozovskiy AG, Bugrova AE, Kononikhin AS, Starodubtseva NL, et
923 al. Mass-Spectrometric Detection of SARS-CoV-2 Virus in Scrapings of the Epithelium of the
924 Nasopharynx of Infected Patients via Nucleocapsid N Protein. *Journal of proteome research*.
925 2020;19(11):4393-7.
- 926 58. Jing L, Chong TM, Byrd B, McClurkan CL, Huang J, Story BT, et al. Dominance and diversity in the
927 primary human CD4 T cell response to replication-competent vaccinia virus. *J Immunol*.
928 2007;178(10):6374-86.
- 929 59. Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, et al. SARS-CoV-2-specific T cell
930 immunity in cases of COVID-19 and SARS, and uninfected controls. *Nature*. 2020;584(7821):457-
931 62.
- 932 60. Nelde A, Bilich T, Heitmann JS, Maringer Y, Salih HR, Roerden M, et al. SARS-CoV-2-derived
933 peptides define heterologous and COVID-19-induced T cell recognition. *Nature immunology*.
934 2021;22(1):74-85.
- 935 61. Oja AE, Saris A, Ghandour CA, Kragten NAM, Hogema BM, Nossent EJ, et al. Divergent SARS-CoV-
936 2-specific T- and B-cell responses in severe but not mild COVID-19 patients. *European journal of
937 immunology*. 2020;50(12):1998-2012.
- 938 62. Peng Y, Mentzer AJ, Liu G, Yao X, Yin Z, Dong D, et al. Broad and strong memory CD4(+) and
939 CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. *Nature
940 immunology*. 2020;21(11):1336-45.
- 941 63. Gordon DE, Hiatt J, Bouhaddou M, Rezelj VV, Ulferts S, Braberg H, et al. Comparative host-
942 coronavirus protein interaction networks reveal pan-viral disease mechanisms. *Science (New
943 York, NY)*. 2020;370(6521).
- 944 64. Jiang HW, Li Y, Zhang HN, Wang W, Yang X, Qi H, et al. SARS-CoV-2 proteome microarray for
945 global profiling of COVID-19 specific IgG and IgM responses. *Nature communications*.
946 2020;11(1):3581.
- 947 65. Wu J, Shi Y, Pan X, Wu S, Hou R, Zhang Y, et al. SARS-CoV-2 ORF9b inhibits RIG-I-MAVS antiviral
948 signaling by interrupting K63-linked ubiquitination of NEMO. *Cell reports*. 2021;34(7):108761.
- 949 66. Tarke A, Sidney J, Methot N, Zhang Y, Dan JM, Goodwin B, et al. Negligible impact of SARS-CoV-2
950 variants on CD4 (+) and CD8 (+) T cell reactivity in COVID-19 exposed donors and vaccinees.
951 *bioRxiv : the preprint server for biology*. 2021.
- 952 67. Agerer B, Koblishcke M, Gudipati V, Montaña-Gutierrez LF, Smyth M, Popa A, et al. SARS-CoV-2
953 mutations in MHC-I-restricted epitopes evade CD8(+) T cell responses. *Science immunology*.
954 2021;6(57).
- 955 68. Yang X, Gao M, Chen G, Pierce BG, Lu J, Weng NP, et al. Structural Basis for Clonal Diversity of
956 the Public T Cell Response to a Dominant Human Cytomegalovirus Epitope. *The Journal of
957 biological chemistry*. 2015;290(48):29106-19.

- 958 69. Laing KJ, Dong L, Sidney J, Sette A, and Koelle DM. Immunology in the Clinic Review Series; focus
959 on host responses: T cell responses to herpes simplex viruses. *Clin Exp Immunol.* 2012;167(1):47-
960 58.
- 961 70. Jing L, Laing KJ, Dong L, Russell RM, Barlow RS, Haas JG, et al. Extensive CD4 and CD8 T Cell
962 Cross-Reactivity between Alphaherpesviruses. *J Immunol.* 2016;196(5):2205-18.
- 963 71. de Silva TI, Liu G, Lindsey BB, Dong D, Moore SC, Hsu NS, et al. The impact of viral mutations on
964 recognition by SARS-CoV-2 specific T-cells. *iScience.* 2021:103353.
- 965 72. Keeton R, Richardson SI, Moyo-Gwete T, Hermanus T, Tincho MB, Benede N, et al. Prior
966 infection with SARS-CoV-2 boosts and broadens Ad26.COVS immunogenicity in a variant-
967 dependent manner. *Cell host & microbe.* 2021.
- 968 73. Choi A, Koch M, Wu K, Chu L, Ma L, Hill A, et al. Safety and immunogenicity of SARS-CoV-2
969 variant mRNA vaccine boosters in healthy adults: an interim analysis. *Nature medicine.* 2021.
- 970 74. Mateus J, Grifoni A, Tarke A, Sidney J, Ramirez SI, Dan JM, et al. Selective and cross-reactive
971 SARS-CoV-2 T cell epitopes in unexposed humans. *Science (New York, NY).* 2020;370(6512):89-
972 94.
- 973 75. Schmidt KG, Nganou-Makamdop K, Tenbusch M, El Kenz B, Maier C, Lapuente D, et al. SARS-
974 CoV-2-Seronegative Subjects Target CTL Epitopes in the SARS-CoV-2 Nucleoprotein Cross-
975 Reactive to Common Cold Coronaviruses. *Frontiers in immunology.* 2021;12:627568.
- 976 76. Mateus J, Dan JM, Zhang Z, Rydzynski Moderbacher C, Lammers M, Goodwin B, et al. Low-dose
977 mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells.
978 *Science (New York, NY).* 2021;374(6566):eabj9853.
- 979 77. Ng KW, Faulkner N, Wrobel AG, Gamblin SJ, and Kassiotis G. Heterologous humoral immunity to
980 human and zoonotic coronaviruses: Aiming for the achilles heel. *Seminars in immunology.*
981 2021:101507.
- 982 78. Aguilar-Bretones M, Westerhuis BM, Raadsen MP, de Bruin E, Chandler FD, Okba NM, et al.
983 Seasonal coronavirus-specific B cells with limited SARS-CoV-2 cross-reactivity dominate the IgG
984 response in severe COVID-19. *The Journal of clinical investigation.* 2021;131(21).
- 985 79. Sagar M, Reifler K, Rossi M, Miller NS, Sinha P, White LF, et al. Recent endemic coronavirus
986 infection is associated with less-severe COVID-19. *The Journal of clinical investigation.*
987 2021;131(1).
- 988 80. Nguyen THO, Rowntree LC, Petersen J, Chua BY, Hensen L, Kedzierski L, et al. CD8(+) T cells
989 specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor
990 frequency and TCR promiscuity. *Immunity.* 2021;54(5):1066-82 e5.
- 991 81. Nolan S, Vignali M, Klinger M, Dines JN, Kaplan IM, Svejnoha E, et al. A large-scale database of T-
992 cell receptor beta (TCRbeta) sequences and binding associations from natural and synthetic
993 exposure to SARS-CoV-2. *Research square.* 2020.
- 994 82. Breton G, Mendoza P, Hagglof T, Oliveira TY, Schaefer-Babajew D, Gaebler C, et al. Persistent
995 cellular immunity to SARS-CoV-2 infection. *J Exp Med.* 2021;218(4).
- 996 83. Fischer DS, Ansari M, Wagner KI, Jarosch S, Huang Y, Mayr CH, et al. Single-cell RNA sequencing
997 reveals ex vivo signatures of SARS-CoV-2-reactive T cells through 'reverse phenotyping'. *Nature*
998 *communications.* 2021;12(1):4515.
- 999 84. Deng X, Gu W, Federman S, du Plessis L, Pybus OG, Faria NR, et al. Genomic surveillance reveals
1000 multiple introductions of SARS-CoV-2 into Northern California. *Science.* 2020;369(6503):582-7.
- 1001 85. Rathe JA, Hemann EA, Eggenberger J, Li Z, Knoll ML, Stokes C, et al. SARS-CoV-2 Serologic Assays
1002 in Control and Unknown Populations Demonstrate the Necessity of Virus Neutralization Testing.
1003 *The Journal of infectious diseases.* 2021;223(7):1120-31.

- 1004 86. Greaney AJ, Loes AN, Crawford KHD, Starr TN, Malone KD, Chu HY, et al. Comprehensive
1005 mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by
1006 polyclonal human plasma antibodies. *Cell host & microbe*. 2021;29(3):463-76.e6.
- 1007 87. Greaney AJ, Starr TN, Gilchuk P, Zost SJ, Binshtein E, Loes AN, et al. Complete Mapping of
1008 Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition.
1009 *Cell host & microbe*. 2021;29(1):44-57.e9.
- 1010 88. Collier DA, De Marco A, Ferreira I, Meng B, Datir RP, Walls AC, et al. Sensitivity of SARS-CoV-2
1011 B.1.1.7 to mRNA vaccine-elicited antibodies. *Nature*. 2021;593(7857):136-41.
- 1012 89. Shu Y, and McCauley J. GISAID: Global initiative on sharing all influenza data - from vision to
1013 reality. *Euro surveillance : bulletin Europeen sur les maladies transmissibles = European*
1014 *communicable disease bulletin*. 2017;22(13).
- 1015 90. Kell A, Stoddard M, Li H, Marcotrigiano J, Shaw GM, and Gale M, Jr. Pathogen-Associated
1016 Molecular Pattern Recognition of Hepatitis C Virus Transmitted/Founder Variants by RIG-I Is
1017 Dependent on U-Core Length. *J Virol*. 2015;89(21):11056-68.
- 1018 91. Esposito D, Mehalko J, Drew M, Snead K, Wall V, Taylor T, et al. Optimizing high-yield production
1019 of SARS-CoV-2 soluble spike trimers for serology assays. *Protein expression and purification*.
1020 2020;174:105686.
- 1021 92. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. Estimated
1022 transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. *Science (New York, NY)*.
1023 2021;372(6538).
- 1024 93. Voloch CM, da Silva Francisco R, Jr., de Almeida LGP, Cardoso CC, Brustolini OJ, Gerber AL, et al.
1025 Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil. *J Virol*.
1026 2021.
- 1027 94. Koelle DM. Expression cloning for the discovery of viral antigens and epitopes recognized by T-
1028 cells. *Methods*. 2003;29:213-26.
- 1029 95. V'Kovski P, Kratzel A, Steiner S, Stalder H, and Thiel V. Coronavirus biology and replication:
1030 implications for SARS-CoV-2. *Nature reviews Microbiology*. 2021;19(3):155-70.
- 1031 96. Koelle DM, Chen HB, Gavin MA, Wald A, Kwok WW, and Corey L. CD8 CTL from genital herpes
1032 simplex lesions: recognition of viral tegument and immediate early proteins and lysis of infected
1033 cutaneous cells. *J Immunol*. 2001;166(6):4049-58.
- 1034 97. Ramirez RD, Sheridan S, Girard L, Sato M, Kim Y, Pollack J, et al. Immortalization of human
1035 bronchial epithelial cells in the absence of viral oncoproteins. *Cancer Res*. 2004;64(24):9027-34.
- 1036 98. Koelle DM, Chen H, Gavin MA, Wald A, Kwok WW, and Corey L. CD8 CTL from genital herpes
1037 simplex lesions: recognition of viral tegument and immediate early proteins and lysis of infected
1038 cutaneous cells. *Journal of Immunology*. 2001;166:4049-58.
- 1039 99. Johnston C, Zhu J, Jing L, Laing KJ, McClurkan CM, Klock A, et al. Virologic and immunologic
1040 evidence of multifocal genital herpes simplex virus 2 infection. *Journal of virology*.
1041 2014;88(9):4921-31.
- 1042 100. Koelle DM, Corey L, Burke RL, Eisenberg RJ, Cohen GH, Pichyangkura R, et al. Antigenic
1043 specificity of human CD4+ T cell clones recovered from recurrent genital HSV-2 lesions. *Journal*
1044 *of virology*. 1994;68:2803-10.
- 1045 101. Yasukawa M, and Zarlring JM. Autologous herpes simplex virus-infected cells are lysed by human
1046 natural killer cells. *Journal of Immunology*. 1983;131(4):2011-6.
- 1047 102. Vita R, Overton JA, Greenbaum JA, Ponomarenko J, Clark JD, Cantrell JR, et al. The immune
1048 epitope database (IEDB) 3.0. *Nucleic Acids Res*. 2015;43(Database issue):D405-12.

1049

Fig.1




Fig. 1. AIM detection and enrichment of SARS-CoV-2 specific T cells in response to whole virus. A: PBMC from participant W003 incubated with inactivated cell-associated SARS-CoV-2 or mock antigen. Gating scheme at top. Lower panels show expression of activation markers CD137 and CD69 in response to 18 hour stimulation amongst CD4 or CD8 T cells. B: Similar layout for subject W005, specimen 1 PBMC stimulated with autologous moDC pre-treated with SARS-CoV-2 or mock antigen. Gating scheme at top. For both stimulation methods, numbers are percentages of gated T cells expressing dual activation markers. C: CD69/CD137 positive CD4 T cells from the pathway in part A: were expanded and tested for reactivity with inactivated cell-associated SARS-CoV-2 or mock antigen. Gated, live, responder, CD3+/CD4+/CD8- cells are shown. Numbers are percent of cells accumulating the indicated cytokines.

Fig.2




Fig. 2. Recognition of infected respiratory epithelial cells by SARS-CoV-2-specific CD8 T cells. A: HBEC3-KT-A cells with or without infection with SARS-CoV-2 were co-cultivated with tetramer-enriched, HLA A*03:01-restricted, S 378-386-specific CD8 T cells and activation measured by IFN- γ secretion. S: spike-specific T cells. M: control MCPyV-specific CD8 T cells. B: Both T cell populations specifically recognized HBEC3-KT-A cells treated with relevant viral peptide.

Fig.3




Fig. 3. SARS-CoV-2 CD8 T cell antigens and epitopes from PBMC stimulation with whole SARS-CoV-2 antigen. A: Subject W005, specimen 1 CD8 TCL were assayed with aAPC expressing each SARS-CoV-2 protein and relevant HLA A and B. Four reactivities were noted. B: Subject W010 CD8 TCL is reactive with HLA A*01:01 aAPC co-transfected with NSP3. For A: and B: negative controls at right. C: CD8 TCL from B: assayed against column (C) and row (R) pooled NSP3 peptides with autologous EBV-LCL as APC. D: Tetramer stain of CD8 TCL before and after sorting and expansion of tetramer-positive cells. Percentages of tetramer-positive cells shown E: Reactivity of tetramer-enriched cells for aAPC transfected with the indicated plasmids or treated with the indicated peptides. F: Dose-response for HLA A*01:01 aAPC with the indicated concentrations of NSP3 1637-1646. Duplicate or triplicate IFN- γ release assays show raw data as bars (A) or dots for each value and means as bars (B, C, E, F).

Fig.4







Fig. 4. Summary of SARS-CoV-2 proteome-level T cell reactivity for PBMC after COVID-19 illness, using AIM enrichment with whole viral antigen. Rows indicate donors and days between recovery from illness and PBMC sampling. Upper 5 rows were studied without DC boosting; lower 12 rows used this procedure. Columns are individual SARS-CoV-2 proteins. A: CD8 TCL scoring positive (purple). B: CD4 TCL scoring positive (red). At right are number of proteins recognized and at bottom are number of subjects with reactivity at one or more time points.

Fig.5

A



B



C




Fig. 5. A: CD4 TCL from PBMC stimulated with moDC and whole SARS-CoV-2 (subjects W001, W005, W012) or PBMC stimulated with whole SARS-CoV-2 (subject W003) recognize whole SARS-CoV-2, and sCoV OC43 or 229E antigens (V), but not mock (M) antigens. B: CD4 TCL from subject W001 recognizes full-length S protein from OC43 but not empty vector control. C: CD4 TCL recognize homologous S peptides from SARS-CoV-2 and OC43 in an HLA DR-restricted fashion as indicated by inhibition with locus-specific mAb. An overlapping SARS-CoV-2 peptide shows DRB1*15:01 restriction at right. Conserved AA are underlined.

Fig.6




Fig. 6. CD8 TCL recognition by SARS-CoV-2 variant peptides. aAPC transfected with HLA A*02:01 and treated with wild-type but not variant peptides were recognized by polyclonal CD8 TCL lines. Lineage B.1.351 is also known as beta and P.1 is also known as gamma).

Fig. 7




Fig. 7. CD4 T cell recognition by SARS-CoV-2 variant peptides. Summary of recognition of spike strain Wu-1 peptides and variants. Donors indicated at top. Each Wu-1 peptide recognized by one or more subject is numbered at left. Coordinates and AA substitutions or deletions of variants tested are listed at right. Variants in WHO VOC indicated with blue square. Color codes at left summarize level of recognition of variant peptide by each T cell. VBM = variants being monitored, VOC = variants of concern per US CDC October 2021